Loading
Virus-based Gene Therapy Research / Cancer, Hypoxia, and Metabolism / Cancer Research and Treatments · Journal article
Signal Transduction and Targeted Therapy · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study identifying a novel functional hypoxia-response element (HRE) in the E1A promoter of enadenotucirev and demonstrating that HIF-2α/HIF-1β heterodimers drive E1A upregulation under hypoxic conditions in vitro. The work characterizes a biological principle but does not establish clinical efficacy or therapeutic superiority and should be viewed as hypothesis-generating evidence for how oncolytic adenoviruses may be activated within hypoxic tumor regions.
In vitro mechanistic study. Cultured cells infected with enadenotucirev under hypoxic conditions; specific lines and eligibility criteria not stated. Intervention: Exposure to hypoxic conditions following enadenotucirev infection. Compared with: Implied normoxic control, but not explicitly detailed in abstract.
E1A upregulated 17-fold within 2 hours after virus entry under hypoxia, driven by conserved HRE in promoter HIF-2α and HIF-1β heterodimers bind the HRE and transactivate E1A Hypoxia enhanced transcription and translation of immediate-early, early, and late adenoviral genes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work provides mechanistic rationale for why oncolytic adenoviruses may preferentially replicate in hypoxic tumor microenvironments, but does not yet establish clinical benefit or superior therapeutic outcomes. Further in vivo efficacy studies and clinical translation are required before clinical recommendations.
Mechanistic in vitro study demonstrating a novel biological principle (HIF-2α-driven E1A upregulation under hypoxia) without clinical outcomes, efficacy data, or in vivo therapeutic validation.
As stated by the source record.
Quoted from the source exactly as published.
This work provides mechanistic rationale for why oncolytic adenoviruses may preferentially replicate in hypoxic tumor microenvironments, but does not yet establish clinical benefit or superior therapeutic outcomes. Further in vivo efficacy studies and clinical translation are required before clinical recommendations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Hypoxia, a hallmark of solid tumors, poses a significant challenge in cancer therapy due to its association with poor prognosis and resistance to conventional treatments. Oncolytic viruses represent a promising treatment strategy, as they selectively replicate within cancer cells and lyse them, potentially including those in hypoxic tumor regions. Here, we examined how hypoxic conditions influence the activity of enadenotucirev (EnAd), a clinically relevant group B oncolytic adenovirus previously detected in hypoxic areas of xenograft tumors. We demonstrated that hypoxia enhances virus production by boosting transcription and translation of immediate-early, early, and late adenoviral genes. The immediate-early gene E1A was upregulated within 2 h (17-fold) after virus entry under hypoxia, driven by a conserved hypoxia-response element (HRE) in its promoter. Mechanistic studies revealed that the hypoxia-inducible factor (HIF)-2α and HIF-1β heterodimers bind to this HRE, transactivating E1A. By inducing E1A expression, hypoxia also elevated viral genome synthesis, structural protein production, and therapeutic transgene expression, underscoring the potential of EnAd to target the hypoxic tumor microenvironment. This is the first report of a functional HRE in a human adenovirus, conserved across 59 adenovirus genotypes, and identifies hypoxia as a driver of enhanced oncolytic activity with implications for adenovirus-based therapies in solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.